Skip to main content
Proto Axiom banner
Proto Axiom logo

Proto Axiom

Australia's first true biotech incubator.

Raised 20M SERIES_B on August 13, 2024

About

Proto Axiom is a hands-on Australian biomedical technology incubator that provides technical oversight, administrative support, research and translational assistance, programmatic grants, and onshoring of IP for early-stage biotech projects.

Mission

Proto Axiom operates as a hands-on biomedical technology incubator, providing technical oversight, administrative support, future financing and research assistance to early-stage biotech projects. The firm emphasizes onshoring Australia’s scientific capacity and keeping downstream IP and economic benefits in-country. Recent activities include a led investment of $2 million in UNSW spin-out Swan Genomics and continued support for portfolio company Endo Axiom as it approaches first-in-human trials for an oral insulin platform. Proto Axiom positions itself as a first-in-country, holistic enterprise model rather than a traditional fund, and runs programming such as the Challenger Summit offering over $250,000 in unencumbered grant financing. Management says the capital will be used to continue strategically investing in and supporting Australia’s best science.

Quick Facts

Founded

2021

Funding

SERIES_B

Industry

Biotechnology, Life Science, Venture Capital

Team Size

1-10

Headquarters

Sydney, New South Wales, Australia